Genus (GENSF) Stock Price, News & Analysis

Company Overview

Genus plc, trading on the OTCMKTS under the symbol GENSF, is a global leader in innovative animal genetics and breeding solutions. The company operates through two primary business segments: ABS and PIC. ABS focuses on bovine genetics, offering dairy and beef cattle semen, advanced reproductive technologies and digital herd management tools. PIC specializes in porcine genetics, providing breeding stock, genetic evaluation services and production support aimed at optimizing growth performance, health and sustainability across the global swine industry.

With origins dating back to its establishment in 1933 as the British Dairy Cattle Breeders’ Society, Genus has expanded through strategic acquisitions and organic growth to build a leading position in animal biotechnology. The company maintains a robust research and development program that leverages genomic selection, precision breeding and data analytics to accelerate genetic gains and address emerging challenges such as disease resistance and environmental impact. Its R&D activities are supported by cutting-edge laboratories, field trial networks and collaborations with academic institutions and industry partners.

Genus serves customers in more than 75 countries, with major operations and sales hubs across North America, Europe, Latin America and Asia-Pacific. Its global infrastructure encompasses production facilities, distribution centers and service teams that deliver genetic material, technical support and training to farmers, integrators and co-operatives. Headquartered in Basingstoke, United Kingdom, Genus is led by an experienced management team with deep expertise in animal health, genomics and agribusiness, driving a focus on sustainable productivity and value creation for stakeholders worldwide.

Key Stats

• Today's Range: $35.15 to $35.15
• 50-Day Range: $26.01 to $35.15
• 52-Week Range: $20.51 to $35.15
• Volume: N/A
• Average Volume: 1,526 shs
• Market Capitalization: N/A
• P/E Ratio: 73.84
• Dividend Yield: 0.47%
• Price Target: N/A
• Consensus Rating: N/A

Genus Stock Analysis - MarketRank™

Genus scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genus.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genus is 73.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genus is 73.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.35.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genus has a short interest ratio ("days to cover") of 38, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Genus pays a meaningful dividend of 1.48%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Genus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Genus is 34.87%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genus has a short interest ratio ("days to cover") of 38, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Genus has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genus insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 29.70% of the stock of Genus is held by institutions.

GENSF Stock Analysis - Frequently Asked Questions

How have GENSF shares performed this year?

Genus' stock was trading at $21.0050 on January 1st, 2025. Since then, GENSF shares have increased by 67.3% and is now trading at $35.15.

How do I buy shares of Genus?

Shares of GENSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:GENSF
• CIK: N/A
• Web: www.genusplc.com
• Phone: 441256347100
• Fax: N/A
• Employees: 3,500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 73.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A